Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · CONMED (CNMD)

CONMED adds $450 million Term A-2 loan to repurchase 2026 convertible notes

Neutral Impact 3 of 5 financing Written later

CONMED entered into an amendment to its credit agreement on May 27, 2026, providing commitments for a $450 million senior secured delayed draw term loan. The company may draw it in a single drawing on or before June 14, 2026, and the loan matures June 10, 2030. Proceeds are earmarked to repurchase part of its 2.25% Convertible Senior Notes due 2026 and to pay related fees and expenses, which adds $450 million of secured debt.

Key points

  • Term A-2 Loan Facility: $450 million, available in a single drawing on or before June 14, 2026
  • Maturity: June 10, 2030, same as existing revolving and term loan facilities
  • Interest: adjusted term SOFR plus 1.125% to 2.25%, or base rate plus 0.125% to 1.25%, based on senior secured leverage; 1.75% and 0.75% until the first adjustment date for the quarter ending September 30, 2026
  • Proceeds to repurchase part of the 2.25% Convertible Senior Notes due 2026 and pay related fees

The filing

CompanyCONMED (CNMD)
Form8-K, current report
Filed with the SECJun 1, 2026, 8:31 AM ET
Accession number0002077096-26-000190

Items reported: 1.01 Material Definitive Agreement2.03 New Direct Financial Obligation

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 01, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.